Supplementary Figure SF1 from Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study
Year: 2024
Type: supplementary-materials
Abstract: Somatic mutations identified by whole exome sequencing. Oncoplot representing the most common somatic mutations assessed by whole exome sequencing (WES) in tumors obtained from patients (n = 23) at the time of diagnosis. Genes with mutations occurring in five or more patients are shown.
Authors: Clinton Yam, Miral Patel, Holly A. Hill, Ryan Sun, Roland L. Bassett, Elisabeth Kong, Senthil Damodaran, Kimberly B. Koenig, Sausan Abouharb, Sadia Saleem, Ajit K. Bisen, Rashmi K. Murthy, David L. Ramirez, Gaiane M. Rauch, Beatriz E. Adrada, Rosalind P. Candelaria, Xiaoping Wang, Elizabeth A. Mittendorf, Alastair M. Thompson, Jason B. White, Elizabeth E. Ravenberg, Alyson R. Clayborn, Qing-Qing Ding, Daniel J. Booser, Oluchi Oke, Abenaa M. Brewster, Gabriel N. Hortobagyi, Nuhad K. Ibrahim, Jennifer K. Litton, Vicente Valero, Banu K. Arun, Debu Tripathy, Jeffrey T. Chang, Ken Chen, Anil Korkut, Stacy L. Moulder, Lei Huo, Bora Lim, Naoto T. Ueno
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4403874974